Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
02/1996
02/27/1996US5494898 Peptide skeletal muscle relaxants
02/27/1996US5494897 Pentapeptides, linear or cyclic
02/27/1996US5494896 Administering bactericidal permeability-increasing protein
02/27/1996US5494895 Scorpion peptide margatoxin with immunosuppressant activity
02/27/1996US5494894 Using a pentapeptide
02/27/1996US5494893 Stylostatin 2
02/27/1996US5494814 Ribonucleotides having two hybridizing regions with predetermined sequences capable of hybridizing with target dna
02/27/1996US5494809 Culturing and incubating cells of bacillus amyloliquefaciens
02/27/1996US5494806 A genetic engineered, hybridized probe consisting of an 18-polynucleotides sequence
02/27/1996US5494802 Tissue antigen and diagnostic method for human osteoporosis using the same
02/27/1996US5494792 Kainate-binding, human CNS receptors of the EAA2 family
02/27/1996US5494791 Monoclonal antibodies against glycated low density lipoprotein
02/27/1996US5494682 Encapsulated biomass in crosslinked polymer material
02/27/1996US5494679 Molecules for iontophoretic delivery
02/27/1996US5494672 Pseudomonas peptide composition and method
02/27/1996US5494670 Method of treating ketosis
02/27/1996US5494665 Metal chloride, lysozyme chloride, isotonic agent, nonionic thickening agent and preservative
02/27/1996US5494663 Treatment of microbial infection with interleukin 1 polypeptides
02/27/1996US5494662 Stimulator for bone formation
02/27/1996CA2156991A1 Compositions which are suitable for employment as antidotes to blood anticoagulants, and their use
02/27/1996CA2156990A1 Pharmaceutical which is suitable for employment as an antidote to blood anticoagulants, and its use
02/26/1996CA2156767A1 Binding agent for growth factor
02/25/1996CA2692337A1 Purification of alpha-1 proteinase inhibitor using novel chromatographic separation conditions
02/24/1996WO1996006181A1 Method of modifying protein
02/22/1996WO1996005322A1 Detection and treatment of breast cancer
02/22/1996WO1996005321A1 Gene therapy for restenosis using an adenoviral vector
02/22/1996WO1996005320A1 Adenovirus comprising a gene coding for glutathion peroxidase
02/22/1996WO1996005319A1 Genetically engineered cells that produce dopamine
02/22/1996WO1996005313A1 VACCINES CONTAINING BORRELIA BURGDORFERI OspG
02/22/1996WO1996005311A1 Biologically active porcine somatotropin polypeptide and methods of using the same
02/22/1996WO1996005309A2 Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
02/22/1996WO1996005308A1 Method for diagnosing a predisposition for breast and ovarian cancer
02/22/1996WO1996005307A2 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE
02/22/1996WO1996005306A2 IN VIVO MUTATIONS AND POLYMORPHISMS IN THE 17q-LINKED BREAST AND OVARIAN CANCER SUSCEPTIBILITY GENE
02/22/1996WO1996005305A1 Use of zrk peptide sequences in contraception
02/22/1996WO1996005304A1 Integrin blocking molecules
02/22/1996WO1996005303A1 Cloning and regulation of an endothelial cell protein c/activated protein c receptor
02/22/1996WO1996005301A1 Novel vesicular acetylcholine carrier
02/22/1996WO1996005300A2 Or-1 on orphan receptor belonging to the nuclear receptor family
02/22/1996WO1996005298A1 Antitumor antisense oligonucleotides
02/22/1996WO1996005297A1 Method of gene therapy using dna vectors without selection marker gene
02/22/1996WO1996005291A1 Recombinant herpesvirus of turkeys and uses thereof
02/22/1996WO1996005289A1 Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
02/22/1996WO1996005288A2 T cell activation
02/22/1996WO1996005232A1 Apoptosis related protein bcl-y, and methods of use thereof
02/22/1996WO1996005231A1 Peptides and antibodies and their use in treatment of carcinomas
02/22/1996WO1996005230A1 MONOCLONAL ANTIBODY AGAINST HUMAN Mx PROTEIN MxA
02/22/1996WO1996005229A1 Human-murine chimeric antibodies against respiratory syncytial virus
02/22/1996WO1996005228A1 METHOD OF PRODUCING SINGLE-CHAIN Fv MOLECULES
02/22/1996WO1996005227A1 Peptides inhibiting the cholesterol ester transfer protein and therapeutic uses thereof
02/22/1996WO1996005226A1 POLYNUCLEOTIDE ENCODING C5a RECEPTOR
02/22/1996WO1996005225A1 Adrenergic receptor
02/22/1996WO1996005224A1 Single-chain forms of the glycoprotein hormone quartet
02/22/1996WO1996005222A1 Purification and pharmaceutical compositions containing type g botulinum neurotoxin
02/22/1996WO1996005221A1 Calcitonin receptor
02/22/1996WO1996005220A1 Compounds for use in treatment of carcinomas
02/22/1996WO1996005219A1 Purified form of streptogramines, preparation thereof and pharmaceutical compositions containing it
02/22/1996WO1996004934A1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum
02/22/1996WO1996004933A2 Cck antibodies used to improve feed efficiency
02/22/1996WO1996004930A1 Transferrin compositions to alleviate the side effects of cytotoxic drugs
02/22/1996WO1996004929A1 Antibacterial composition containing multimeric alpha-lactalbumin
02/22/1996WO1996004928A1 Calcitonin gene related peptide receptor
02/22/1996WO1996004927A1 NOVEL GnRH ANALOGUES WITH ANTITUMOUR EFFECTS AND PHARMACEUTICAL COMPOSITIONS THEREOF
02/22/1996WO1996004926A1 TWO NON-CONTIGUOUS REGIONS CONTRIBUTE TO NIDOGEN BINDING TO A SINGLE EGF-LIKE MOTIF OF THE LAMININ η1 CHAIN
02/22/1996WO1996004925A1 Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
02/22/1996WO1996004916A1 Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
02/22/1996WO1996004790A1 Dna encoding a human betaine/gaba transporter and uses thereof
02/22/1996WO1996004789A1 A method of selectively destroying neoplastic cells
02/22/1996WO1996004787A1 Combined virustatic antimediator (covam) treatment of common colds
02/22/1996WO1995025171A3 Dna sequences for matrix metalloproteases, their production and use
02/22/1996DE4418691A1 3'-(4'-) nicht-radioaktiv markierte Nukleoside und Nukleotide mit Aminocarbonsäure-, Peptid- oder Carbonsäure-Spacer 3 '- (4') non-radioactively labeled nucleosides and nucleotides with aminocarboxylic acid, peptide or carboxylic acid-spacer
02/22/1996DE19530509A1 Prepn. of solid, stomach-acid resistant pharmaceutical prepns.
02/22/1996CA2197801A1 T cell activation
02/22/1996CA2197712A1 Vaccines containing borrelia burgdorferi ospg
02/22/1996CA2197497A1 Novel vesicular acetylcholine carrier
02/22/1996CA2197232A1 Method of producing single-chain fv molecules
02/22/1996CA2196756A1 Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
02/22/1996CA2196594A1 Use of antibodies to cck to improve feed efficiency
02/22/1996CA2196208A1 Retroviral vectors produced by producer cell lines resistant to lysis by human serum
02/22/1996CA2196203A1 Combined virustatic antimediator (covam) treatment of common colds
02/22/1996CA2196053A1 Two non-contiguous regions contribute to nidogen binding to a single egf-like motif of the laminin .gamma.1 chain
02/22/1996CA2174232A1 Gene therapy for restenosis using an adenoviral vector
02/22/1996CA2173727A1 Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof
02/21/1996EP0697414A1 Compounds and methods for inhibiting propagation of human immunodeficiency virus
02/21/1996EP0697403A1 Derivatives of glycinamides as cholecystokinin receptor agonists
02/21/1996EP0697218A2 Method of preparing cross-linked biomaterial compositions for use in tissue augmentation
02/21/1996EP0697214A1 Liposomal cyclosporin pharmaceutical formulations
02/21/1996EP0696920A1 Improved pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug
02/21/1996EP0696919A1 Diagnosis and treatment of erectile dysfunction
02/21/1996EP0560795B1 38-decarboxy-38-hydroxymethyl derivatives of teicoplanin antibiotics, and a process for preparing them
02/21/1996EP0516785B1 RECOMBINANT ANTIBODIES SPECIFIC FOR TNF alpha
02/21/1996EP0474767B1 Dopamine agonists
02/21/1996CN1117266A Stable protein: phospholipid compositions and methods
02/21/1996CN1117051A Anti-cancer active matter Huogu mushroom essence and its extracting process
02/21/1996CN1116953A Hematoma liquefier
02/21/1996CN1116952A Hematoma liquefier
02/21/1996CN1116951A Oral recombination human Gamma interferon (IF) composite
02/21/1996CN1031038C Prolonged release of biologically active polyepeptides
02/20/1996US5493009 Antiidiotypic monoclonal antibodies MK2-23 anti-melanomal antibody 763.74
02/20/1996US5493008 Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain
1 ... 2802 2803 2804 2805 2806 2807 2808 2809 2810 2811 2812 2813 2814 2815 2816 2817 2818 2819 2820 2821 2822 ... 3163